Table 1.

In vivo efficacy of IL13 dTc

GroupMedian survival (range), dLong-term survivors (>120 d), %P
Tumor, no treatment (n = 4)35 (35–38)0<0.03 vs. no treatment
Tumor + UnTd T cells (n = 10)40 (29–53)0<0.0001 vs. no treatment; <0.0001 vs. UnTd T cells
Tumor + IL13 dTc (n = 11)88 (47–120+)28